Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabies vaccine for non-specific protection against common infectious diseases
NCT03656198Phase 4Completed
- Sponsor
- Ross University School of Veterinary Medicine
- Start
- Aug 2018
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of rabies virus inactivated antigen, A in influenza-like illness (ILI), upper respiratory tract infection (URI), diarrhea and 1 more (2 arms), sponsored by Ross University School of Veterinary Medicine. Primary endpoint: Number of self-reported new episodes of acute common infectious disease at 26 weeks. Started Aug 2018; status: completed.
02
Drugs
rabies virus inactivated antigen, A
03
Conditions
influenza-like illness (ILI)upper respiratory tract infection (URI)diarrheafever
Beyond the preview
Go deeper on NCT03656198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656198.